Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effect of isosorbide-5-mononitrate on exercise performance and clinical status in patients with congestive heart failure - Results of the nitrates incongestive heart failure (NICE) study
Autore:
Lewis, BS; Rabinowitz, B; Schlesinger, Z; Caspi, A; Markiewicz, W; Rosenfeld, T; Sclarovsky, S; Ermer, W;
Indirizzi:
Lady Davis Carmel Med Ctr, Dept Cardiol, IL-34362 Haifa, Israel Lady DavisCarmel Med Ctr Haifa Israel IL-34362 , IL-34362 Haifa, Israel
Titolo Testata:
CARDIOLOGY
fascicolo: 1, volume: 91, anno: 1999,
pagine: 1 - 7
SICI:
0008-6312(1999)91:1<1:EOIOEP>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; INTRAVENOUS ISOSORBIDE DINITRATE; VASODILATOR THERAPY; CARDIAC-OUTPUT; TOLERANCE; CAPTOPRIL; HYDRALAZINE; ENALAPRIL; CAPACITY; DISEASE;
Keywords:
exercise performance; heart failure; pharmacotherapy; nitrates;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Lewis, BS LadylDavis Carmel Med Ctr, Dept Cardiol, 7 Michal St, IL-34362 Haifa, Israe Lady Davis Carmel Med Ctr 7 Michal St Haifa Israel IL-34362 rae
Citazione:
B.S. Lewis et al., "Effect of isosorbide-5-mononitrate on exercise performance and clinical status in patients with congestive heart failure - Results of the nitrates incongestive heart failure (NICE) study", CARDIOLOGY, 91(1), 1999, pp. 1-7

Abstract

Background and Aims: Nitrate therapy improves hemodynamics in patients with heart failure, but the chronic effects of oral nitrates on exercise performance and clinical status have not been well studied. Methods: Oral isosorbide-5-mononitrate (ISMN) (50 mg once daily) or placebo was administered to136 patients (NYHA Class 2-3) treated for heart failure, all receiving captopril and most also furosemide. Endpoints were treadmill exercise time at 12 weeks by modified Naughton protocol (primary), with an additional 12-week follow-up period. Secondary endpoints included left ventricular dimensions, ejection fraction, cardiothoracic ratio, functional class, quality of life, hospitalizations and plasma norepinephrine and atrial natriuretic peptide in a four-center sub-study. Results: Intention-to-treat analysis showed that mean change in treadmill exercise duration tended to be greater in patients receiving ISMN than placebo (treatment difference +42 s, 95% CI -5, +90 s at 12 weeks and +21 s, 95% CI -25, +74 s after 24 weeks) (NS). Treatment difference was greater in the prespecified subgroup with ejection fraction 31-40% (+55 s, 95% CI -11, +136 s at 12 weeks and +65 s, 95% CI +3, +147s) (p = 0.035) at 24 weeks. No deleterious effects (i.e. hypotension) wereobserved with ISMN, although headache was reported in 19% of the active treatment group (p = 0.0001). Conclusions: ISMN added to captopril increased treadmill exercise time in patients with heart failure and a lesser reduction in baseline ejection fraction, although for the group as a whole, the increase in treadmill time was not significant.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 08:30:25